Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Covalon Technologies Ltd V.COV

Alternate Symbol(s):  CVALF

Covalon Technologies Ltd. is a patient-driven medical device company. Through a portfolio of patented technologies and solutions for advanced wound care, infection prevention, and medical device coatings, the Company offers gentler and more compassionate options for patients to heal with less infections, less pain, and better outcomes. Its solutions are designed for patients and made for care providers. It leverages its patented medical technology platforms and expertise in two ways: by developing products that are sold under Covalon’s name and by developing and commercializing medical products for other medical companies under development and license contracts. It provides a range of specialized medical devices, medical dressings and advanced medical technology designed for infection prevention, complex wound closure and perioperative care. Its perioperative care solutions provide antimicrobial protection of pre-operative skin, through postoperative incision care to scar prophylaxis.


TSXV:COV - Post by User

Bullboard Posts
Post by TheMonolithon Jul 22, 2019 2:11pm
107 Views
Post# 29947586

Lack of EPS

Lack of EPSThis seems to be a hangup for a contingent of shareholders.  While I would love to see more EPS, it's not what I personally am focused on for Covalon.  It takes a great deal of resources to build out the framework and infrastructure.  They have many high margin deals that could hit with new SKUs and divisions.  Once they have a much more established sales distribution network in the US and and Europe, EPS can become more of a foucs.  

I'm happy to watch them grow the business as the priority, and if they can come close to breakeven, that's fine by me.  

Licensing deals were alluded to in the last CC, and that will be the rocket sauce a shareholder should keep their eyes open for.  
Bullboard Posts